Resultados: 4

J. bras. econ. saúde (Impr.); 11 (2), 2019

Objective: To perform a cost-minimization analysis comparing the cohort with the current average patient weight of 70 kg (MoH current assumption). Since most rheumatoid arthritis (RA) patients in Brazil are women (60 kg or less), we also aimed to define this percentage at Brazilian public healthcare syst...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 10 (2), 2018

Background: Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia. Lipegfilgrastim is a long-acting, once-per-cycle G-CSF, while Brazil’s standard of care is short-acting filgrastim. A cost-effectiveness and budget impact analysis of lipegfilgrastim was con...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 9 (Suplemento 1), 2017

Objective: This study aimed to verify the variation on antipsychotics costs according to four unit costs paid by public health providers in Brazil. Methods: This cross-sectional study used the health provider perspective and bottom-up approach to evaluate 134 subjects with mental disorders, in regular us...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 8 (3), 2017

Objectives: The aim of this study was to describe the socio-demographic and clinical variables, identify the determinants of length of stay and estimate the cost of inpatient treatment of schizophrenia in Minas Gerais, Brazil. Methods: A non-concurrent cohort was conducted in three psychiatric hospitals ...

Texto completo (link principal)     Texto completo (link alternativo)